Production of high plasticity stem cells
By isolating and activating dormant guide cells from adult tissues to generate highly plastic stem cells (giaSC), the ethical and tumorigenicity issues of existing stem cell therapies are resolved, achieving highly efficient tissue regeneration and therapeutic effects.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- APSTEM THERAPEUTICS INC
- Filing Date
- 2024-10-04
- Publication Date
- 2026-05-26
AI Technical Summary
Existing stem cell therapies face challenges such as ethical issues, tumorigenicity, and low yield, failing to provide highly plastic adult stem cells for the treatment of tissue damage and degenerative diseases.
Dormant guide cells with a diameter of less than 6 micrometers are isolated from adult tissues, activated, and brought into contact with somatic cells to generate highly plastic stem cells (giaSCs) through cell-cell interactions. These cells have transgerm layer differentiation potential and are non-tumorigenic.
The generated giaSC can be expanded in vitro and can adapt to the host environment in vivo, actively regenerating and reconstructing tissues, solving the ethical and tumorigenicity issues of existing stem cell therapies and providing a highly efficient treatment option.
Smart Images

Figure FT_1 
Figure FT_2 
Figure FT_3